Effect of inhaled dry powder mannitol on mucus and its clearance

Expert Review of Respiratory Medicine

Volumn 7, Issue 1, 2013, Pages 65-75

  Daviskas, Evangelia ^a   Rubin, Bruce K ^b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

asthma; bronchiectasis; cough; cystic fibrosis; mannitol; mucus clearance; rheology; sputum

Indexed keywords

BRONCHODILATING AGENT; CARBOHYDRATE; DNA; DORNASE ALFA; F ACTIN; GLOBULAR PROTEIN; GLYCOPROTEIN; MANNITOL; MUCIN; MUCOLYTIC AGENT; OLIGOSACCHARIDE; OSMOTIC AGENT; SODIUM CHLORIDE; WATER;

ASTHMA; BRONCHIECTASIS; BRONCHIOLE; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CILIATED EPITHELIUM; COUGHING; CYSTIC FIBROSIS; EUKARYOTIC FLAGELLUM; HUMAN; HYPEROSMOLARITY; INFLAMMATION; LONG TERM CARE; LUNG CLEARANCE; MUCOCILIARY CLEARANCE; MUCUS; NEUTROPHIL; PHASE 3 CLINICAL TRIAL (TOPIC); POWDER INHALER; REVIEW; SPUTUM; VISCOELASTICITY;

EID: 84873200853     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.12.72     Document Type: Review

References (90)

1. Satir P, Sleigh MA. The physiology of cilia and mucociliary interactions. Annu. Rev. Physiol. 52, 137-155 (1990). (Pubitemid 20103531)
2. Tarran R. Regulation of airway surface liquid volume and mucus transport by active ion transport. Proc. Am. Thorac. Soc. 1(1), 42-46 (2004).
3. Cole PJ. Inflammation: a two-edged sword -the model of bronchiectasis. Eur. J. Respir. Dis. Suppl. 147, 6-15 (1986). (Pubitemid 16017382)
4. Verdugo P. Mucin exocytosis. Am. Rev. Respir. Dis. 144(3 Pt 2), S33-S37 (1991).
5. Tarran R, Grubb BR, Gatzy JT, Davis CW, Boucher RC. The relative roles of passive surface forces and active ion transport in the modulation of airway surface liquid volume and composition. J. Gen. Physiol. 118(2), 223-236 (2001). (Pubitemid 32744527)
6. Davies JR, Herrmann A, Russell W, Svitacheva N, Wickström C, Carlstedt I. Respiratory tract mucins: structure and expression patterns. Novartis Found. Symp. 248, 76-88; discussion 88 (2002).
7. Rose MC, Voynow JA. Respiratory tract mucin genes and mucin glycoproteins in health and disease. Physiol. Rev. 86(1), 245-278 (2006).
8. Verdugo P. Goblet cells secretion and mucogenesis. Annu. Rev. Physiol. 52, 157-176 (1990). (Pubitemid 20103532)
9. Dasgupta B, King M. Molecular basis for mucolytic therapy. Can. Respir. J. 2(4), 223-230 (1995).
10. King M. The role of mucus viscoelasticity in cough clearance. Biorheology 24(6), 589-597 (1987). (Pubitemid 18021584)
11. Puchelle E, Zahm JM. Influence of rheological properties of human bronchial secretions on the ciliary beat frequency. Biorheology 21(1-2), 265-272 (1984). (Pubitemid 14051600)
12. Puchelle E, Jacquot J, Beck G, Zahm JM, Galabert C. Rheological and transport properties of airway secretions in cystic fibrosis -relationships with the degree of infection and severity of the disease. Eur. J. Clin. Invest. 15(6), 389-394 (1985). (Pubitemid 16185748)
13. King M, Zahm JM, Pierrot D, Vaquez-Girod S, Puchelle E. The role of mucus gel viscosity, spinnability, and adhesive properties in clearance by simulated cough. Biorheology 26(4), 737-745 (1989). (Pubitemid 19214135)
14. Girod S, Zahm JM, Plotkowski C, Beck G, Puchelle E. Role of the physiochemical properties of mucus in the protection of the respiratory epithelium. Eur. Respir. J. 5(4), 477-487 (1992).
15. Girod S, Fuchey C, Galabert C et al. Identification of phospholipids in secretory granules of human submucosal gland respiratory cells. J. Histochem. Cytochem. 39(2), 193-198 (1991).
16. Im Hof V, Gehr P, Gerber V, Lee MM, Schürch S. In vivo determination of surface tension in the horse trachea and in vitro model studies. Respir. Physiol. 109(1), 81-93 (1997). (Pubitemid 27327002)
17. Gehr P, Green FH, Geiser M, Im Hof V, Lee MM, Schürch S. Airway surfactant, a primary defense barrier: mechanical and immunological aspects. J. Aerosol Med. 9(2), 163-181 (1996). (Pubitemid 26192804)
18. Vaquez-Girod S, Zahm JM, Dionisius JP, Pierrot D, Puchelle E. Automatic measurement of the wetting properties of biological fluids. Innov. Tech. Biol. Med. 9, 402-412 (1988).
19. Rubin BK. Surface properties of respiratory secretions: relationship to mucus transport. In: Cilia, Mucus, and Mucociliary Interactions. Baum G, Priel Z, Roth YNL, Ostfield E (Eds). Marcel Dekker, NY, USA, 317-324 (1998).
20. Boucher RC. Relationship of airway epithelial ion transport to chronic bronchitis. Proc. Am. Thorac. Soc. 1(1), 66-70 (2004).
21. Boucher RC. Evidence for airway surface dehydration as the initiating event in CF airway disease. J. Intern. Med. 261(1), 5-16 (2007). (Pubitemid 46046468)
22. Sheils CA, Käs J, Travassos W et al. Actin filaments mediate DNA fiber formation in chronic inflammatory airway disease. Am. J. Pathol. 148(3), 919-927 (1996). (Pubitemid 126660683)
23. Tomkiewicz RP, Rubin BK. DNA and Actin filament ultrastructure in cystic fibrosis sputum. In: Cilia, Mucus, and Mucociliary Interactions. Baum G, Priel Z, Roth YNL, Ostfield E (Eds). Marcel Dekker, NY, USA, 333-341 (1998).
24. Lopez-Vidriero MT, Reid L. Chemical markers of mucous and serum glycoproteins and their relation to viscosity in mucoid and purulent sputum from various hypersecretory diseases. Am. Rev. Respir. Dis. 117(3), 465-477 (1978). (Pubitemid 8311200)
25. Shah SA, Santago P, Rubin BK. Quantification of biopolymer filament structure. Ultramicroscopy 104(3-4), 244-254 (2005). (Pubitemid 40982467)
26. Girod S, Galabert C, Lecuire A, Zahm JM, Puchelle E. Phospholipid composition and surface-active properties of tracheobronchial secretions from patients with cystic fibrosis and chronic obstructive pulmonary diseases. Pediatr. Pulmonol. 13(1), 22-27 (1992).
27. Hite RD, Seeds MC, Jacinto RB, Balasubramanian R, Waite M, Bass D. Hydrolysis of surfactant-associated phosphatidylcholine by mammalian secretory phospholipases A2. Am. J. Physiol. 275(4 Pt 1), L740-L747 (1998).
28. Enhorning G. Surfactant in airway disease. Chest 133(4), 975-980 (2008). (Pubitemid 351536875)
29. Daviskas E, Anderson SD, Jaques A, Charlton B. Inhaled mannitol improves the hydration and surface properties of sputum in patients with cystic fibrosis. Chest 137(4), 861-868 (2010).
30. Zahm JM, Pierrot D, Vaquez-Girod S, Duvivier C, King M, Puchelle E. The role of mucus sol phase in clearance by simulated cough. Biorheology 26(4), 747-752 (1989). (Pubitemid 19214136)
31. King M, Brock G, Lundell C. Clearance of mucus by simulated cough. J. Appl. Physiol. 58(6), 1776-1782 (1985). (Pubitemid 15013835)
32. Foster WM. Mucociliary transport and cough in humans. Pulm. Pharmacol. Ther. 15(3), 277-282 (2002).
33. Matsui H, Verghese MW, Kesimer M et al. Reduced three-dimensional motility in dehydrated airway mucus prevents neutrophil capture and killing bacteria on airway epithelial surfaces. J. Immunol. 175(2), 1090-1099 (2005). (Pubitemid 41094995)
34. King M, Rubin BK. Pharmacological approaches to discovery and development of new mucolytic agents. Adv. Drug Deliv. Rev. 54(11), 1475-1490 (2002). (Pubitemid 35375771)
35. App EM, Baran D, Dab I et al. Dose-finding and 24-h monitoring for efficacy and safety of aerosolized nacystelyn in cystic fibrosis. Eur. Respir. J. 19(2), 294-302 (2002). (Pubitemid 34162831)
36. Zahm JM, Girod de Bentzmann S, Deneuville E et al. Dose-dependent in vitro effect of recombinant human DNase on rheological and transport properties of cystic fibrosis respiratory mucus. Eur. Respir. J. 8(3), 381-386 (1995).
37. Griese M, App EM, Duroux A, Burkert A, Schams A, Derouix A. Recombinant human DNase (rhDNase) influences phospholipid composition, surface activity, rheology and consecutively clearance indices of cystic fibrosis sputum. Pulm. Pharmacol. Ther. 10(1), 21-27 (1997). (Pubitemid 27470231)
38. Zahm JM, Galabert C, Chaffin A, Chazalette JP, Grosskopf C, Puchelle E. Improvement of cystic fibrosis airway mucus transportability by recombinant human DNase is related to changes in phospholipid profile. Am. J. Respir. Crit. Care Med. 157(6 Pt 1), 1779-1784 (1998).
39. O'Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest 113(5), 1329-1334 (1998). (Pubitemid 28223825)
40. Wills PJ, Wodehouse T, Corkery K, Mallon K, Wilson R, Cole PJ. Short-term recombinant human DNase in bronchiectasis. Effect on clinical state and in vitro sputum transportability. Am. J. Respir. Crit. Care Med. 154(2 Pt 1), 413-417 (1996). (Pubitemid 26269112)
41. Hirsh AJ. Altering airway surface liquid volume: inhalation therapy with amiloride and hyperosmotic agents. Adv. Drug Deliv. Rev. 54(11), 1445-1462 (2002). (Pubitemid 35378659)
42. Daviskas E, Anderson SD. Hyperosmolar agents and clearance of mucus in the diseased airway. J. Aerosol Med. 19(1), 100-109 (2006).
43. Matsui H, Grubb BR, Tarran R et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 95(7), 1005-1015 (1998). (Pubitemid 29019052)
44. Matsui H, Davis CW, Tarran R, Boucher RC. Osmotic water permeabilities of cultured, well-differentiated normal and cystic fibrosis airway epithelia. J. Clin. Invest. 105(10), 1419-1427 (2000). (Pubitemid 30322407)
45. Chen BT, Yeates DB. Ion transport and regulation of respiratory tract fluid output in dogs. J. Appl. Physiol. 90(3), 821-831 (2001). (Pubitemid 32171364)
46. Daviskas E, Anderson SD, Young IH. Inhaled mannitol changes the sputum properties in asthmatics with mucus hypersecretion. Respirology 12(5), 683-691 (2007). (Pubitemid 47414869)
47. Daviskas E, Anderson SD, Young IH. Effect of mannitol and repetitive coughing on the sputum properties in bronchiectasis. Respir. Med. 104(3), 371-377 (2010).
48. Daviskas E, Anderson SD, Gomes K et al. Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum. Respirology 10(1), 46-56 (2005). (Pubitemid 40343762)
49. Daviskas E, Anderson SD, Eberl S, Chan HK, Young IH. The 24-h effect of mannitol on the clearance of mucus in patients with bronchiectasis. Chest 119(2), 414-421 (2001). (Pubitemid 32163751)
50. Zahm JM, King M, Duvivier C, Pierrot D, Girod S, Puchelle E. Role of simulated repetitive coughing in mucus clearance. Eur. Respir. J. 4(3), 311-315 (1991).
51. Rubin BK. Mucus structure and properties in cystic fibrosis. Paediatr. Respir. Rev. 8(1), 4-7 (2007). (Pubitemid 46523785)
52. Bilton D, Robinson P, Cooper P et al.; CF301 Study Investigators. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. Eur. Respir. J. 38(5), 1071-1080 (2011).
53. Aitken ML, Bellon G, De Boeck K et al.; CF302 Investigators. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am. J. Respir. Crit. Care Med. 185(6), 645-652 (2012).
54. Bennett WD, Daviskas E, Hasani A, Mortensen J, Fleming J, Scheuch G. Mucociliary and cough clearance as a biomarker for therapeutic development. J. Aerosol Med. Pulm. Drug Deliv. 23(5), 261-272 (2010).
55. Daviskas E, Anderson SD, Gonda I, Chan HK, Cook P, Fulton R. Changes in mucociliary clearance during and after isocapnic hyperventilation in asthmatic and healthy subjects. Eur. Respir. J. 8(5), 742-751 (1995).
56. Robinson M, Eberl S, Tomlinson C et al. Regional mucociliary clearance in patients with cystic fibrosis. J. Aerosol Med. 13(2), 73-86 (2000). (Pubitemid 30421866)
57. Daviskas E, Anderson SD, Brannan JD, Chan HK, Eberl S, Bautovich G. Inhalation of dry-powder mannitol increases mucociliary clearance. Eur. Respir. J. 10(11), 2449-2454 (1997). (Pubitemid 28048614)
58. Sood N, Bennett WD, Zeman K et al. Increasing concentration of inhaled saline with or without amiloride: effect on mucociliary clearance in normal subjects. Am. J. Respir. Crit. Care Med. 167(2), 158-163 (2003). (Pubitemid 36076074)
59. Feng W, Nakamura S, Sudo E, Lee MM, Shao A, King M. Effects of dextran on tracheal mucociliary velocity in dogs in vivo. Pulm. Pharmacol. Ther. 12(1), 35-41 (1999). (Pubitemid 29201618)
60. Winters SL, Yeates DB. Roles of hydration, sodium, and chloride in regulation of canine mucociliary transport system. J. Appl. Physiol. 83(4), 1360-1369 (1997). (Pubitemid 27433106)
61. Yaghi A, Zaman A, Dolovich MB. The direct effect of hyperosmolar agents on ciliary beating of human bronchial epithelial cells. J. Aerosol Med. Pulm. Drug Deliv. 25(2), 88-95 (2012).
62. Lourenço RV, Loddenkemper R, Carton RW. Patterns of distribution and clearance of aerosols in patients with bronchiectasis. Am. Rev. Respir. Dis. 106(6), 857-866 (1972).
63. Currie DC, Pavia D, Agnew JE et al. Impaired tracheobronchial clearance in bronchiectasis. Thorax 42(2), 126-130 (1987). (Pubitemid 17020314)
64. Isawa T, Teshima T, Hirano T et al. Mucociliary clearance and transport in bronchiectasis: global and regional assessment. J. Nucl. Med. 31(5), 543-548 (1990). (Pubitemid 20179691)
65. Daviskas E, Anderson SD, Eberl S, Chan HK, Bautovich G. Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am. J. Respir. Crit. Care Med. 159(6), 1843-1848 (1999). (Pubitemid 29275053)
66. O'Riordan TG, Zwang J, Smaldone GC. Mucociliary clearance in adult asthma. Am. Rev. Respir. Dis. 146, 598-603 (1992).
67. Daviskas E, Anderson SD, Shaw J et al. Mucociliary clearance in patients with chronic asthma: effects of beta agonists. Respirology 10(4), 426-435 (2005). (Pubitemid 43942610)
68. Daviskas E, Anderson SD, Eberl S, Young IH. Beneficial effect of inhaled mannitol and cough in asthmatics with mucociliary dysfunction. Respir. Med. 104(11), 1645-1653 (2010).
69. Regnis JA, Robinson M, Bailey DL et al. Mucociliary clearance in patients with cystic fibrosis and in normal subjects. Am. J. Respir. Crit. Care Med. 150(1), 66-71 (1994). (Pubitemid 24209938)
70. Robinson M, Daviskas E, Eberl S et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. Eur. Respir. J. 14(3), 678-685 (1999). (Pubitemid 29479736)
71. Daviskas E, Anderson SD, Eberl S, Young IH. Effect of increasing doses of mannitol on mucus clearance in patients with bronchiectasis. Eur. Respir. J. 31(4), 765-772 (2008).
72. Glover W, Chan HK, Eberl S, Daviskas E, Verschuer J. Effect of particle size of dry powder mannitol on the lung deposition in healthy volunteers. Int. J. Pharm. 349(1-2), 314-322 (2008). (Pubitemid 350299704)
73. Teper A, Jaques A, Charlton B. Inhaled mannitol in patients with cystic fibrosis: A randomised open-label dose response trial. J. Cyst. Fibros. 10(1), 1-8 (2011).
74. Kellett F, Redfern J, Niven RM. Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis. Respir. Med. 99(1), 27-31 (2005). (Pubitemid 40017380)
75. Kellett F, Robert NM. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. Respir. Med. 105(12), 1831-1835 (2011).
76. Nicolson CH, Stirling RG, Borg BM, Button BM, Wilson JW, Holland AE. The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Respir. Med. 106(5), 661-667 (2012).
77. Yeates DB, Chen BT. Increases in airway surface liquid induced by the administration of near-isoosmotic and hypertonic mannitol aerosols. J. Aerosol. Med. 12, 112 (1999).
78. Tarran R, Grubb BR, Parsons D et al. The CF salt controversy: in vivo observations and therapeutic approaches. Mol. Cell 8(1), 149-158 (2001). (Pubitemid 32772913)
79. Feng W, Garrett H, Speert DP, King M. Improved clearability of cystic fibrosis sputum with dextran treatment in vitro. Am. J. Respir. Crit. Care Med. 157(3 Pt 1), 710-714 (1998).
80. King M. Mucoactive therapy: what the future holds for patients with cystic fibrosis. Pediatric Pulmonol. 14(3), 678-685 (1997).
81. Hasani A, Chapman TH, McCool D, Smith RE, Dilworth JP, Agnew JE. Domiciliary humidification improves lung mucociliary clearance in patients with bronchiectasis. Chron. Respir. Dis. 5(2), 81-86 (2008).
82. Kishioka C, Okamoto K, Kim JS, Rubin BK. Hyperosmolar solutions stimulate mucus secretion in the ferret trachea. Chest 124(1), 306-313 (2003). (Pubitemid 36851367)
83. Wanner A, Salathé M, O'Riordan TG. Mucociliary clearance in the airways. Am. J. Respir. Crit. Care Med. 154(6 Pt 1), 1868-1902 (1996). (Pubitemid 26424963)
84. Rubin BK. Mucus, phlegm, and sputum in cystic fibrosis. Respir. Care 54(6), 726-732; discussion 732 (2009).
85. Jia Y, Lee LY. Role of TRPV receptors in respiratory diseases. Biochim. Biophys. Acta 1772(8), 915-927 (2007). (Pubitemid 47176369)
86. Brannan JD, Anderson SD, Perry CP, Freed-Martens R, Lassig AR, Charlton B; Aridol Study Group. The safety and efficacy of inhaled dry powder mannitol as a bronchial provocation test for airway hyperresponsiveness: a Phase 3 comparison study with hypertonic (4.5%) saline. Respir. Res. 6, 144 (2005).
87. Daviskas E, Turton JA, Anderson SD, Young IH, Lassig A, Charlton B. A placebo controlled trial with inhaled mannitol improves health related quality of life in patients with bronchiectasis. Eur. Resp. J. 24(Suppl. 48), 707 (2004).
88. Bilton D, Daviskas E, Jaques A, Anderson SD, Charlton B. A randomised, placebo controlled trial of inhaled mannitol in patients with bronchiectasis. Am. J. Respir. Crit. Care Med. 179, A3221 (2009).
89. Jaques A, Daviskas E, Turton JA et al. Inhaled mannitol improves lung function in cystic fibrosis. Chest 133(6), 1388-1396 (2008). (Pubitemid 351892995)
90. Voynow JA, Rubin BK. Mucins, mucus, and sputum. Chest 135(2), 505-512 (2009).